NEUPRO
PeakNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
May 2007
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
6/8 — Strong
NEUPRO by UCB Pharma is non-ergoline dopamine agonist. Approved for parkinson's disease, moderate-to-severe primary restless legs syndrome. First approved in 2007.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEUPRO (rotigotine) is a nonergot dopamine agonist delivered via transdermal film for extended-release treatment of Parkinson's disease and restless legs syndrome. It works by stimulating dopamine receptors in the brain to restore motor control and reduce symptom burden. The transdermal delivery system provides continuous dopaminergic therapy with improved tolerability compared to oral formulations.
$93MPart D
Peak5.3 years to LOEPeak-stage product with stable Medicare utilization (~79K claims annually) suggests mature brand team focused on retention and lifecycle management rather than aggressive expansion.
Mechanism of Action
non-ergoline dopamine agonist. The precise mechanism of action of rotigotine as a treatment for Parkinson's disease is unknown, although it is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen in the brain. The precise mechanism of action of rotigotine…
Worked on NEUPRO at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.